Market cap of Coherus BioSciences, Inc.
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non?small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
|ADVM Adverum Biotechnologies, Inc.||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||178.78|
|SNDX Syndax Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||189.52|
|SCYX SCYNEXIS, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||192.25|
|ASMB Assembly Biosciences, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||200.56|
|TPHS Trinity Place Holdings Inc.||NYSEMKT > Consumer Services > Building operators||201.35|
|SYRS Syros Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||229.04|
|CHRS Coherus BioSciences, Inc.||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||238.12|
|LJPC La Jolla Pharmaceutical Company||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||8,824.21|
|RARE Ultragenyx Pharmaceutical Inc.||NASDAQ > Health Care > Major Pharmaceuticals||10,880.38|
|RIOT Riot Blockchain, Inc||NASDAQ > Health Care > Biotechnology: In Vitro & In Vivo Diagnostic Substances||14,181.75|
|ADMS Adamas Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||22,090.90|
|GLYC GlycoMimetics, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||26,375.14|
|PRKR ParkerVision, Inc.||NASDAQ > Technology > Radio And Television Broadcasting And Communications Equipment||91,633.80|